The role of volumetric High-Resolution computed tomography (HRCT) of the chest in the assessment of patients with stable chronic obstructive pulmonary disease (COPD)

NCT ID NCT07809399

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 ยท Last updated Sep 09, 2026

Summary

This study evaluates the role of volumetric high-resolution computed tomography (HRCT) of the chest in assessing patients with stable chronic obstructive pulmonary disease (COPD). COPD is a heterogeneous lung condition characterized by chronic pulmonary symptoms, structural airway/alveolar changes, and progressive airflow limitation. While spirometry provides a global assessment of lung function, it cannot localize or fully characterize specific structural abnormalities. Volumetric HRCT allows for detailed, quantitative imaging of lung parenchyma, emphysema extent, air trapping, and airway wall thickness. The primary objective of this cross-sectional observational study is to quantify emphysema, air trapping, and bronchial wall thickness in patients with stable COPD and to evaluate the relationship between these volumetric HRCT findings and clinical measures of disease severity. By identifying objective imaging parameters, this study aims to improve patient evaluation, disease staging, and clinical management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

75 people

The number who actually took part.

Started

Apr 2025

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients attending the smoking clinic and chest disease general clinic at Mansoura University Hospital who have stable COPD confirmed by pulmonary function testing.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:Patients with stable chronic obstructive pulmonary disease (COPD) Diagnosed according to GOLD criteria (post-bronchodilator FEV1/FVC \< 0.70) \- Exclusion Criteria: 1. Patient in exacerbation defined as change in the patient's baseline dyspnea, cough, and/or sputum beyond normal day-to-day variations within 14 days . (Ko, Fanny W., et al 2016) 2. Connective tissue disease . 3. Previously diagnosed Interstitial lung disease 4. Contraindication to PFT According to ATS (Stanojevic S., et al 2021) * Recent Myocardial Infarction Within 1 week * Blood Pressure Instability Severe hypertension or systemic hypotension * Arrhythmias Significant, uncontrolled atrial or ventricular arrhythmias * Decompensated heart failure * Pulmonary Circulation Issues: Uncontrolled pulmonary hypertension, acute cor pulmonale, or clinically unstable pulmonary embolism * History of Syncope Loss of consciousness related to coughing or forced expiration * Cerebral Aneurysm * Recent Brain Surgery: Within 4 weeks * Concussion: Recent concussion with prolonged symptoms * Eye Surgery: Recent eye surgery within 1 week * Pneumothorax: Active or untreated pneumothorax Recent Thoracic Surgery: Within 4 weeks Recent Abdominal Surgery: Within 4 weeks Late-Term Pregnancy 5. Contraindicatins of 6MWT according to ATS : Absolute contraindications * Unstable Angina Experienced during the previous 1 month. * Recent Myocardial Infarction : Within the previous 1 month. Relative contraindications * Resting Tachycardia: Resting heart rate \> 120{ bpm}. * Severe Uncontrolled Hypertension: * Systolic Blood Pressure \> 180{ mmHg} * Diastolic Blood Pressure \> 100{ mmHg} * Symptomatic/Severe Cardiac Conditions: High-degree atrioventricular (AV) block, hypertrophic cardiomyopathy, or symptomatic severe aortic stenosis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Airway obstruction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mansoura University Hospital (Chest Disease Department)

    Al Mansurah, Dakahlia Governorate, 35516, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.